CA1128859A - Tissue adhesive - Google Patents

Tissue adhesive

Info

Publication number
CA1128859A
CA1128859A CA344,717A CA344717A CA1128859A CA 1128859 A CA1128859 A CA 1128859A CA 344717 A CA344717 A CA 344717A CA 1128859 A CA1128859 A CA 1128859A
Authority
CA
Canada
Prior art keywords
fibrinogen
tissue adhesive
set forth
inhibitor
cryoprecipitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA344,717A
Other languages
French (fr)
Inventor
Otto Schwarz
Yendra Linnau
Franz Loblich
Thomas Seelich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG fuer Chemisch Medizinische Produkte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3508534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1128859(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno AG fuer Chemisch Medizinische Produkte filed Critical Immuno AG fuer Chemisch Medizinische Produkte
Application granted granted Critical
Publication of CA1128859A publication Critical patent/CA1128859A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ABSTRACT OF THE DISCLOSURE:

A tissue adhesive on the basis of human or animal pro-tein contains factor XIII and at least 33 % by weight of fibrinogen, has a ratio of factor XIII to fibrinogen, ex-pressed in units of factor XIII per gram of fibrinogen, of at least 80, contains fibrinogen and albumin in the overall protein at a ratio of 33 to 90 : 5 to 40, contains plasmino-gen-activator-inhibitor or plasmin inhibitor in an amount of 250 to 25,000 KIU per g of fibrinogen and has been lyophilized.

Description

1~8~

The invention relates to a tissue adhesive on the basis of human or animal proteins, containing fibrinogen and factor XIII.
It has been known for long to use blood coagulating substances for stopping bleedings and for sealing wounds.
According to the first proposals of this kind, fibrin tampons and fibrin platelets, respectively, were used.
During the Second World War, tissue adherences by means of blood plasma were suggested.
In recent times, a tissue adhesive on the basis of fibrinogen and factor XIII for seamless interfascicular nerve transplantations in animal experiments has been described by H. Matras et al. in "Wiener Medizinischen Wochenschrift", 1972, page 517.
A further study was carried out by Spangler et al.
in "Wiener Klinischen Wochenschrift", 1973, pages 1 to 7.
Also there, the possibility was shown in animal experiments of carrying out a tissue adherence with the aid of fibri-nogen as a cryoprecipitate and thrombin.
The known preparatlons have not yet proved satis-factory, since they do not sufficiently meet the demands set to a tissue adhesive, i.e.
a) high straining capacity of the adherences and wound sealings as well as safe and permanent blood stopping, i.e. good adhering capacity of the adhesive to the wound and tissue surfaces, as well as hi~h internal strength of the same, ; b) controllable durability of the adherences in the body, c) complete absorbability of the adhesive in the course 3~

8~3S~

of the wound healing process, (d) wound healing stimulating properties.
This may partly be due to the fact that, in the known preparat-ions the coagulation factors necessary for blood stopping have not been present in an optimal proportion to one another, and also to the fact that the fibrinolytic activity in the area of adher-ence has not been sufficiently under control. Premature disso-lutions of the tissue adherences frequently occurred due to enzymatic influence.
The invention aims at avoiding these disadvantages and difficulties and has as its object to provide a lyophilized tissue adhesive of human or animal origin, which meets the demandsset out further above and which is present in a lyophili-zed form, which is desir~d for its longer durability and better transporting and storing properties.
Accordingly, the invention provides a tissue adhesive on the basis of human or animal proteins and containing fibrino-gen and factor XIII, which tissue adhesive is characterized in that (a) it contains at least 33% by weight of fibrinogen, (b)- the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounts to at least 80, (c) fibrinogen and albumin are contained in the total protein at a ratio of 33 to 90 : 5 to ~0, (d) it has a content of plasminogen-activator-inhibitor or plasmin-inhibitor, preferably aprotinin, in an amount of 250 to 25,000 Kallikrein-inactivator-units (KIU) per gram of fibrinogen, (e) the preparation has been lyophilized.
According to a preferred embodiment the tissue adhe-~L%88~i~

sive additionally contains glycine, whereby the resolubility of the lyophilized product is improved.
Furthermore, the tissue adhesive additionally may contain glucose or sucrose, which components also improve the solubility.
The tissue adhesive furthermore may contain 0.2 to 200 International Units (IU) of heparin per gram of fibrinogen, whereby a stabilizing effect is obtained.
The tissue adhesive according to the invention posses-ses characteristic cross-linking prop~ertiés after the dis-solution, which are determinable by the sodium-dodecyl-sul-phate-(SDS)-polyacrylamide-gel-electrophoresis method. The test is carried out in that, after mixing of the tissue ad-hesive with an equal volume of a solution containing 40 ~Moles of CaCl2 and 15 NIH-units (U.S. National Institute of Health units) of thrombin per ml, the mixture is incu-bated at 37C. The cross-linking degree is determined by a gel electrophoresis after stopping of the reaction and reductive splitting of the disulphide bridges contained in the proteins by the addition of a mixture of urea, sodium dodecyl sulphate and ~-mercaptoethanol. Typical of the tissue adhesive according to the invention is a complete cross-linking of the fibrin-~-chains after 3 to 5 minutes, and a cross-linking of at least 35 ~ of the fibrin-~ chains a ter two hours.
Fibrinogen, albumin and cold-insoluble globulin, in the total protein, are to be present in the tissue adhesive ac-cording to the invention at a certain ratio; this ratio amounts to 33 to 90 : 5 to 40 : 0.2 to 15.
The invention moreover comprises a method of producing 81~S~3 the tissue adhesive described from plasma cryoprecipitate, which method comprises:
removing from the cryoprecipitate plasma-protein that is soluble in the cold, by treating the cryoprecipitate with a buffer solution containing sodium citrate, sodium chloride, glycine, glucose, a plasminogen-activator-inhibitor or plasmin-inhibitor, and h~parin, dissolving the purified precipitate, adding human albumin, and lyophilizing the resulting solution.
Advantageously, the cryoprecipitate has been produced of human or animal fresh plasma frozen at -20C. When in-creasing the temperature to 0 to 2C the cryoprecipitate is gained and separated by centrifugation. The precipitate is eluted by a single or repeated elution with the buffer solution having a pH of 6 to 8.0, and centrifuged at 0 to 4C in order to remove the plasma-protein that is soluble in the cold. The treat-ment with the buffer solution is carried out until the desired factor-XIII-fibrinogen ratio is reached.
The purified precipitate is dissolved with a further buffer solution containing human albumin, glycine and, if desired, glucose or sucrose, a plasminogen-activator-inhibitor or plasmin inhibitor as well as heparin, and having a pH of 6.5 to 9.0, and is diluted to a protein concentration of 4.~0 to 9.0 ~. The solution is filtered through a membrane filter having a pore size of down to 0.2 )um, filled into final containers and lyophilized.
The lyophilized tissue adhesive thus obtained can be stored at room temperature or preferably at ~4C; it is ready for use after reconstitution with aqua ad iniectabilia, to which~
if desired, a plasminogen-activator-inhibitor , . ~
,,, l ~1~8~5~

or a plasmin inhibitor, preferably aprotinin, can be added.
When dissolving the lyophilized preparation, attention has to be paid that the solution ready for use contains at least 70 mg of fibrinogen per ml.
The tissue adhesive according to the invention can be applied universally. It can be used for seamless connection of human or animal tissue or organ parts, for sealing wounds and stopping bleedings as well as for stimulating wound healings.
Preferred fields of application in which the tissue adhesive can be successfully used are: indications in the field of ear, nose and throat surgery, oral surgery, dentistry, neurosurgery, plastic surger~7, general sur~ery, abdominal surgery, thorax and vascular surgery, orthopaedics, accident surgery, urology, ophthalmology and gynaecology.
Advantageously,a mixture of thrombin and calcium chloride is added to the adhesive prior to the application of the tissue adhesive according to the invention or is applied onto the tissues to be connected.
The method of the lnvention is explained in more detail by way of the following example:
21 l of human plasma, which had been frozen at -20C, were heated to +2C. The resulting cryoprecipitate (435 ~) was separated by centrifugation at +2C and treated at +2C
with 4.3 l of a buffer solution adjusted at a pH of 6.5 and containing 6.6 g of Na3-citrate.2H20, 3.4 g of NaCl, 10.0 g of glycine, 13.0 of glucose.1H20~ 50,000 KIU of aprotinin and 200 IU of heparin per l, and again centrifuged at +2C.
The separated precipitate was dissolved in a further buffer 3G solution having a pH of 7.9 and containing 35.0 g of human ~z~

albumin, 20.0 g of glycine, 50,000 ~IU of aprotinin and 200 IU of heparin per l, and diluted to a concentration of 70 mg of protein per ml.
Then the solution was sterilized by filtration through membrane filters having a pore size of down to 0.2 ~m, fill-ed into final containers at 2.2 ml each, deepfrozen and lyo-philized. After reconstitution of the lyophilized product to a fibrinogen concentration of ~0 mg/ml, the tissue adhesive preparation ready for use showed, in the cross-linking test, complete fibrin-~-cross-linking after S minutes and 66 %
fibrin-~-cross-linking after 2 hours at 37C.
The ratio of the proteins fibrinogen to albumin to cold-insoluble globulin, contained in the tissue adhesive, was determined to be 64.0 : 22.3 : 7.7. The heparin content was 4.5 IU per g of fibrinogen. Aprotinin was contained at a concentration of 1,133 KIU per g of fibrinogen. The con-tent of factor XIII amounted to 161 units per g of fibrino-gen. The total protein content in the lyophilized prepara-t~on was 72.2 %, the content of fibrinogen in the lyophilized preparation was 46.2 %.
The determinations were carried out in the following manner: The determination of the factor-XIII-units was per-formed by means of a cross-linking test, in which factor-XIII-free fibrinogen was used as a substrate and the fibrin cross-linking caused by the addition of the unknown diluted sample served as a measure for the amount of factor XIII
contained therein~ A corresponding calibration curve was obtained with pooled human citrate plasma, 1 ml plasma con-taining 1 unit of factor XIII per definitionem. The quanti-tative protein determinations were carried out by the method ~1~8~5~

according to Kjeldahl.
The determination of the proteins relative to oneanother was also performed by the SDS-polyacrylamide-gel-electrophoresis method, i.e. a) with a non-reduced sample of the tissue adhesive and b) with a sample reduced with ~-mercaptoethanol.

Claims (11)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A tissue adhesive on the basis of human or animal pro-teins and containing fibrinogen and factor XIII, which tissue adhesive is characterized in that a) it contains at least 33 % by weight of fibrinogen, b) the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounts to at least 80, c) fibrinogen and albumin are contained in the total protein at a ratio of 33 to 90 : 5 to 40, d) it contains plasminogen-activator-inhibitor or plasmin inhibitor in an amount of 250 to 25,000 KIU per g of fibrinogen, and e) it is lyophilized.
2. A tissue adhesive as set forth in claim 1, wherein the plasminogen-activator-inhibitor or plasmin-inhibitor is aprotinin.
3. A tissue adhesive as set forth in claim 1, further con-taining glycine.
4. A tissue adhesive as set forth in claim 1, further con-taining glucose.
5. A tissue adhesive as set forth in claim 1, further con-taining sucrose.
6. A tissue adhesive as set forth in claim 1, which con-tains 0.2 to 200 IU of heparin per g of fibrinogen.
7. A tissue adhesive as set forth in claim 1 being capable, after dissolution of the lyophilized preparation of com-plete cross-linking of the fibrin-?-chains after 3 to 5 minutes of incubation, and of at least 35 % cross-linking of the fibrin-?-chains after 2 hours of incubation, deter-mined according to the SDS-polyacrylamide-gel-electrophor-esis method.
8. A tissue adhesive as set forth in claim 1, wherein the ratio of fibrinogen to albumin to cold-insoluble globulin in the total protein is 33 to 90 : 5 to 40 : 0.2 to 15.
9. A method of producing a tissue adhesive as set forth in claim 1 from plasma cryoprecipitate, which method com-prises removing from the cryoprecipitate plasma-protein that is soluble in the cold, by treating the cryoprecipitate with a buffer solution containing sodium citrate, sodium chloride, glycine, glucose, a plasminogen-activator-in-hibitor or plasmin-inhibitor, and heparin, dissolving the purified precipitate, adding human albumin, and lyophilizing the resulting solution.
10. A method as set forth in claim 9, wherein the cryopreci-pitate is treated once with said buffer solution.
11. A method as set forth in claim 9, wherein the cryoprecipitate is treated several times with said buffer solution.
CA344,717A 1979-02-15 1980-01-30 Tissue adhesive Expired CA1128859A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1189/79 1979-02-15
AT118979A AT359652B (en) 1979-02-15 1979-02-15 METHOD FOR PRODUCING A TISSUE ADHESIVE

Publications (1)

Publication Number Publication Date
CA1128859A true CA1128859A (en) 1982-08-03

Family

ID=3508534

Family Applications (1)

Application Number Title Priority Date Filing Date
CA344,717A Expired CA1128859A (en) 1979-02-15 1980-01-30 Tissue adhesive

Country Status (14)

Country Link
US (2) US4362567A (en)
JP (1) JPS55110556A (en)
AT (1) AT359652B (en)
BE (1) BE881466A (en)
CA (1) CA1128859A (en)
CH (1) CH649711A5 (en)
DE (1) DE3002934C2 (en)
DK (1) DK150815B (en)
ES (1) ES488430A0 (en)
FR (1) FR2448900A1 (en)
GB (1) GB2041942B (en)
IT (1) IT1141211B (en)
NL (1) NL190714B (en)
SE (2) SE453799C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290918A (en) * 1993-02-23 1994-03-01 Haemacure Biotech Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT359652B (en) * 1979-02-15 1980-11-25 Immuno Ag METHOD FOR PRODUCING A TISSUE ADHESIVE
DE3105624A1 (en) * 1981-02-16 1982-09-02 Hormon-Chemie München GmbH, 8000 München MATERIAL FOR SEALING AND HEALING Wounds
EP0068047B1 (en) * 1981-06-25 1986-07-23 Serapharm GmbH & Co. KG Enriched plasma derivative for promoting wound sealing and wound healing
US4442655A (en) * 1981-06-25 1984-04-17 Serapharm Michael Stroetmann Fibrinogen-containing dry preparation, manufacture and use thereof
EP0068149A3 (en) * 1981-06-25 1983-07-20 Serapharm GmbH & Co. KG Dry preparation containing fibrinogene, its production and use
AT369990B (en) * 1981-07-28 1983-02-25 Immuno Ag METHOD FOR PRODUCING A TISSUE ADHESIVE
DE3203775A1 (en) * 1982-02-04 1983-08-11 Behringwerke Ag, 3550 Marburg FIBRINOGEN PREPARATION, METHOD FOR THEIR PRODUCTION AND THEIR USE
DE3214337C2 (en) * 1982-04-19 1984-04-26 Serapharm - Michael Stroetmann, 4400 Münster Resorbable flat material for sealing and healing wounds and processes for their manufacture
US4515637A (en) * 1983-11-16 1985-05-07 Seton Company Collagen-thrombin compositions
JP2648301B2 (en) * 1983-12-27 1997-08-27 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド Vector containing auxiliary DNA for transformation of eukaryotic cells
US4600574A (en) * 1984-03-21 1986-07-15 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Method of producing a tissue adhesive
EP0166263A1 (en) * 1984-05-31 1986-01-02 Green Cross Corporation Filler composition for filling in defect or hollow portion of bone and kit or set for the preparation of the filler composition
US4627879A (en) * 1984-09-07 1986-12-09 The Trustees Of Columbia University In The City Of New York Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma
US4928603A (en) * 1984-09-07 1990-05-29 The Trustees Of Columbia University In The City Of New York Method of preparing a cryoprecipitated suspension and use thereof
AT390001B (en) * 1984-09-28 1990-03-12 Immuno Ag METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASES
AT382783B (en) * 1985-06-20 1987-04-10 Immuno Ag DEVICE FOR APPLICATING A TISSUE ADHESIVE
JPS6323670A (en) * 1986-04-25 1988-01-30 バイオ−ポリマ−ズ　インコ−ポレ−テツド Adhesive coating composition and its production
DE3622642A1 (en) * 1986-07-05 1988-01-14 Behringwerke Ag ONE-COMPONENT TISSUE ADHESIVE AND METHOD FOR THE PRODUCTION THEREOF
DK475386D0 (en) * 1986-10-03 1986-10-03 Weis Fogh Ulla Sivertsen METHOD AND APPARATUS FOR MANUFACTURING BIOLOGICAL SUBSTANCES
CH673117A5 (en) * 1986-12-10 1990-02-15 Ajinomoto Kk
FR2618784B1 (en) * 1987-07-30 1990-04-06 Lille Transfusion Sanguine CONCENTRATE OF THROMBIN-COAGULABLE PROTEINS, PROCESS FOR OBTAINING SAME AND ITS USE AS A BIOLOGICAL GLUE
US5260420A (en) * 1987-07-30 1993-11-09 Centre Regional De Transfusion Sanguine De Lille Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
AT407834B (en) * 1987-10-08 2001-06-25 Aventis Behring Gmbh Single-component tissue adhesive and process for its preparation
EP0341007B1 (en) * 1988-05-02 1994-09-14 Project Hear Surgical adhesive material
AT397203B (en) * 1988-05-31 1994-02-25 Immuno Ag FABRIC ADHESIVE
US4837379A (en) * 1988-06-02 1989-06-06 Organogenesis Inc. Fibrin-collagen tissue equivalents and methods for preparation thereof
DE3829524A1 (en) * 1988-08-31 1990-03-01 Behringwerke Ag USE OF TRANSGLUTAMINASES AS IMMUNE SUPPRESSIVA
FR2639958B1 (en) * 1988-12-06 1992-08-21 Lille Transfusion Sanguine BIOLOGICAL SUPPORT FOR CELL CULTURES CONSISTING OF PLASMATIC PROTEINS COAGULATED BY THROMBIN, ITS USE FOR THE CULTURE OF KERATINOCYTES, THEIR RECOVERY AND THEIR TRANSPORT FOR THERAPEUTIC USE
US5226877A (en) * 1989-06-23 1993-07-13 Epstein Gordon H Method and apparatus for preparing fibrinogen adhesive from whole blood
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5209776A (en) * 1990-07-27 1993-05-11 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5420250A (en) * 1990-08-06 1995-05-30 Fibrin Corporation Phase transfer process for producing native plasma protein concentrates
US5644032A (en) * 1990-08-06 1997-07-01 Fibrin Corporation Process for producing fibrinogen concentrates
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US7208179B1 (en) 1990-11-27 2007-04-24 The American National Red Cross Methods for treating disease and forming a supplemented fibrin matrix
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
CA2097063C (en) * 1990-11-27 2006-08-08 Howard P. Greisler Tissue sealant and growth factor containing compositions that promote accelerated wound healing
US6093558A (en) * 1991-07-25 2000-07-25 Edge Biosystems, Inc. Binding protein of biologically active compositions to an adhesive formulation on a substrate
WO1993005067A1 (en) * 1991-09-05 1993-03-18 Baxter International, Inc. Topical fibrinogen complex
WO1993005822A1 (en) * 1991-09-27 1993-04-01 Octapharma Ag Tissue glue prepared by using cryoprecipitate
US5190057A (en) * 1991-12-13 1993-03-02 Faezeh Sarfarazi Sarfarazi method of closing a corneal incision
US5385606A (en) * 1992-07-06 1995-01-31 Kowanko; Nicholas Adhesive composition and method
FR2696095B1 (en) * 1992-09-30 1994-11-25 Inoteb Biological glue based on proteins coagulable by thrombin, enriched in platelet factors, its preparation and its application.
US5330974A (en) * 1993-03-01 1994-07-19 Fibratek, Inc. Therapeutic fibrinogen compositions
US5552452A (en) * 1993-03-15 1996-09-03 Arch Development Corp. Organic tissue glue for closure of wounds
FR2705235B1 (en) * 1993-05-13 1995-07-13 Inoteb Use of particles of a biocompatible and bioresorbable calcium salt as an active ingredient in the preparation of a medicament for the local treatment of demineralizing bone diseases.
US5653730A (en) * 1993-09-28 1997-08-05 Hemodynamics, Inc. Surface opening adhesive sealer
US5843124A (en) * 1993-09-28 1998-12-01 Hemodynamics, Inc. Surface opening adhesive sealer
US5759194A (en) * 1993-09-28 1998-06-02 Hemodynamics, Inc. Vascular patch applicator
JPH09504719A (en) * 1993-11-03 1997-05-13 クラリオン、ファーマシューティカルズ、インコーポレイテッド Hemostatic patch
US5411885A (en) * 1993-12-17 1995-05-02 New York Blood Center, Inc. Methods for tissue embedding and tissue culturing
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
DE758903T1 (en) * 1994-03-31 1997-07-10 Fibrin Corp CONCENTRATES OF CRYOPRECIPTED, NATURAL FIBRINOGEN
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US5660873A (en) * 1994-09-09 1997-08-26 Bioseal, Limited Liability Corporaton Coating intraluminal stents
ES2218553T3 (en) * 1994-10-11 2004-11-16 Ajinomoto Co., Inc. STABILIZED TRANSGLUTAMINASE AND ENZYMATIC PREPARATION CONTAINING IT.
US5464471A (en) * 1994-11-10 1995-11-07 Whalen Biomedical Inc. Fibrin monomer based tissue adhesive
US5585007A (en) * 1994-12-07 1996-12-17 Plasmaseal Corporation Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant
EP0804257B1 (en) * 1995-01-16 2003-07-09 Baxter International Inc. Self-supporting sheet-like material of cross-linked fibrin for preventing post operative adhesions
US5733545A (en) * 1995-03-03 1998-03-31 Quantic Biomedical Partners Platelet glue wound sealant
US5674394A (en) * 1995-03-24 1997-10-07 Johnson & Johnson Medical, Inc. Single use system for preparation of autologous plasma
US5643192A (en) * 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
AU712934B2 (en) 1995-06-06 1999-11-18 Interpore International Inc. Device and method for concentrating plasma
DE19521324C1 (en) * 1995-06-12 1996-10-31 Immuno Ag Tissue adhesive and use thereof as a hemostatic
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
DE69734557T2 (en) * 1996-03-15 2006-07-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute SPRAYING DEVICE FOR APPLYING TISSUE ADHESIVE
WO2000062828A1 (en) 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
DE19617369A1 (en) * 1996-04-30 1997-11-06 Immuno Ag Storage-stable fibrinogen preparations
EP0917444A1 (en) 1996-07-12 1999-05-26 Baxter Travenol Laboratories, Inc. A fibrin delivery device and method for forming fibrin on a surface
US7435425B2 (en) 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US6066325A (en) * 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US20090324721A1 (en) 1996-09-23 2009-12-31 Jack Kennedy Hydrogels Suitable For Use In Polyp Removal
US7009034B2 (en) 1996-09-23 2006-03-07 Incept, Llc Biocompatible crosslinked polymers
US8003705B2 (en) 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
WO1998012274A1 (en) * 1996-09-23 1998-03-26 Chandrashekar Pathak Methods and devices for preparing protein concentrates
FR2757770B1 (en) * 1996-12-30 1999-02-26 Inoteb PROCESS FOR THE PREPARATION OF A BIOLOGICAL GLUE CAPABLE OF COAGULATING BY SIMPLE ADDITION OF CALCIUM IONS
US6096309A (en) * 1997-06-18 2000-08-01 Cohesion Technologies, Inc. Compositions containing thrombin and microfibrillar nanometer collagen, and methods for preparation and use thereof
AT406120B (en) 1997-08-28 2000-02-25 Immuno Ag TISSUE ADHESIVE
DE19755023C2 (en) * 1997-12-11 2000-03-09 Celanese Chem Europe Gmbh Catalyst and process for making vinyl acetate
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
US6884230B1 (en) 1998-03-09 2005-04-26 Baxter International Inc. Dispensing head for a tissue sealant applicator and process of use
US6274090B1 (en) 1998-08-05 2001-08-14 Thermogenesis Corp. Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
US6994686B2 (en) * 1998-08-26 2006-02-07 Neomend, Inc. Systems for applying cross-linked mechanical barriers
US6921380B1 (en) 1998-10-01 2005-07-26 Baxter International Inc. Component mixing catheter
US7279001B2 (en) * 1998-11-06 2007-10-09 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
WO2000027327A1 (en) 1998-11-12 2000-05-18 Polymer Biosciences, Inc. Hemostatic polymer useful for rapid blood coagulation and hemostasis
WO2000033764A1 (en) * 1998-12-04 2000-06-15 Pathak Chandrashekhar P Biocompatible crosslinked polymers
US6310036B1 (en) 1999-01-09 2001-10-30 Last Chance Tissue Adhesives Corporation High strength, Bio-compatible tissue adhesive and methods for treating vigorously bleeding surfaces
US7662179B2 (en) * 1999-04-09 2010-02-16 Sarfarazi Faezeh M Haptics for accommodative intraocular lens system
US8556967B2 (en) * 1999-04-09 2013-10-15 Faezeh Mona Sarfarazi Interior bag for a capsular bag and injector
US20030007954A1 (en) 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
US6472162B1 (en) 1999-06-04 2002-10-29 Thermogenesis Corp. Method for preparing thrombin for use in a biological glue
ES2206298T3 (en) * 1999-08-13 2004-05-16 Omrix Biopharmaceuticals S.A. USE OF FIBRINOGEN MULTIMERS IN FIBRINE SHOOTING AGENTS.
US6916911B1 (en) 1999-08-13 2005-07-12 Omrix Biopharmaceuticals Sa Use of fibrinogen multimers
US7078232B2 (en) 1999-08-19 2006-07-18 Artecel, Inc. Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
US6429013B1 (en) 1999-08-19 2002-08-06 Artecel Science, Inc. Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
US6463335B1 (en) 1999-10-04 2002-10-08 Medtronic, Inc. Temporary medical electrical lead having electrode mounting pad with biodegradable adhesive
NZ518692A (en) * 1999-12-23 2004-08-27 Csl Ltd Purified fibrinogen free of destabilising levels of plasminogen and other proteases obtained from a Fraction I paste
US20030209612A1 (en) * 2000-07-17 2003-11-13 Kevin Hahnen Spray head for applying a multi-component mixture
AU2002213194A1 (en) * 2000-10-13 2002-04-22 Baxter Healthcare S.A. Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation
US6648911B1 (en) 2000-11-20 2003-11-18 Avantec Vascular Corporation Method and device for the treatment of vulnerable tissue site
US20020082620A1 (en) * 2000-12-27 2002-06-27 Elaine Lee Bioactive materials for aneurysm repair
US6468660B2 (en) 2000-12-29 2002-10-22 St. Jude Medical, Inc. Biocompatible adhesives
US7175336B2 (en) 2001-01-26 2007-02-13 Depuy Acromed, Inc. Graft delivery system
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US20020173770A1 (en) * 2001-05-16 2002-11-21 Flory Alan R. Adhesive delivery system
MXPA04006438A (en) 2001-12-31 2005-06-08 Ares Lab Llc Hemostatic compositions and methods for controlling bleeding.
US7374678B2 (en) 2002-05-24 2008-05-20 Biomet Biologics, Inc. Apparatus and method for separating and concentrating fluids containing multiple components
US7992725B2 (en) 2002-05-03 2011-08-09 Biomet Biologics, Llc Buoy suspension fractionation system
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US20030205538A1 (en) 2002-05-03 2003-11-06 Randel Dorian Methods and apparatus for isolating platelets from blood
AU2003249642A1 (en) 2002-05-24 2003-12-12 Biomet Manufacturing Corp. Apparatus and method for separating and concentrating fluids containing multiple components
US7845499B2 (en) 2002-05-24 2010-12-07 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US20060278588A1 (en) 2002-05-24 2006-12-14 Woodell-May Jennifer E Apparatus and method for separating and concentrating fluids containing multiple components
AU2003270401B2 (en) * 2002-09-10 2008-03-13 American National Red Cross Hemostatic dressing
US7135027B2 (en) 2002-10-04 2006-11-14 Baxter International, Inc. Devices and methods for mixing and extruding medically useful compositions
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US7927626B2 (en) * 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US20050125033A1 (en) * 2003-12-04 2005-06-09 Mcnally-Heintzelman Karen M. Wound closure apparatus
US20050125015A1 (en) * 2003-12-04 2005-06-09 Mcnally-Heintzelman Karen M. Tissue-handling apparatus, system and method
US7659052B2 (en) * 2004-06-29 2010-02-09 Cheng Yao Su Medium comprising cryoprecipitate and method for preserving platelets, red blood cells and other cells without a nucleus
TWI270375B (en) * 2004-06-29 2007-01-11 Cheng-Yao Su A method for preserving platelets outside a living body
US8137450B2 (en) * 2004-07-08 2012-03-20 Symatese Collagen-based lyophilised glue and the use thereof for producing an adhesive prosthesis
WO2006021584A2 (en) * 2004-08-27 2006-03-02 Novo Nordisk Health Care Ag Purification of factor xiii polypeptides from biological materials
WO2006026652A2 (en) * 2004-08-30 2006-03-09 Iken Tissue Therapeutics, Inc. Conditioned medium comprising wnt proteins to promote repair of damaged tissue
ATE540974T1 (en) 2004-11-23 2012-01-15 Zymogenetics Inc PURIFICATION OF RECOMBINANT HUMAN FACTOR XIII
US7866485B2 (en) 2005-02-07 2011-01-11 Hanuman, Llc Apparatus and method for preparing platelet rich plasma and concentrates thereof
EP2910258B1 (en) 2005-02-07 2018-08-01 Hanuman LLC Platelet rich plasma concentrate apparatus
WO2006086201A2 (en) 2005-02-07 2006-08-17 Hanuman Llc Platelet rich plasma concentrate apparatus and method
JP2008530305A (en) 2005-02-09 2008-08-07 タイコ ヘルスケア グループ エルピー Synthetic sealant
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20060212106A1 (en) * 2005-03-21 2006-09-21 Jan Weber Coatings for use on medical devices
JP2008546686A (en) * 2005-06-17 2008-12-25 セレゲン，インコーポレーテッド Method for treating ischemic tissue
FR2887883B1 (en) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement PROCESS FOR SEPARATING FIBRINOGEN PROTEINS, FACTOR XIII AND BIOLOGICAL GLUE OF SOLUBILIZED PLASMA FRONTION AND PREPARATION OF LYOPHILIZED CONCENTRATES OF SAID PROTEINS
FR2894831B1 (en) 2005-12-16 2008-02-15 Lab Francais Du Fractionnement THROMBIN FREE BIOLOGICAL GLUE AND USE THEREOF AS MEDICAMENT.
US8567609B2 (en) 2006-05-25 2013-10-29 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
MX2008014847A (en) 2006-05-31 2009-04-30 Baxter Int Method for directed cell in-growth and controlled tissue regeneration in spinal surgery.
TWI436793B (en) 2006-08-02 2014-05-11 Baxter Int Rapidly acting dry sealant and methods for use and manufacture
CN101522228A (en) 2006-08-02 2009-09-02 克赫里昂恩克斯公司 Implantable preparation, useful more particularly for tissue complement and cicatrisation
EP2059205B1 (en) * 2006-08-04 2012-04-04 Stb Lifesaving Technologies, Inc. Processes for the production of solid dressing for treating wounded tissue
EP2061486A4 (en) * 2006-09-13 2011-11-16 Southeastern Medical Technologies Llc Methods and compositions for sealing and adhering biological tissues and medical uses thereof
US20090227981A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
US20090227689A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
JP5393447B2 (en) 2007-03-22 2014-01-22 一般財団法人化学及血清療法研究所 Solid fibrinogen preparation
US8328024B2 (en) 2007-04-12 2012-12-11 Hanuman, Llc Buoy suspension fractionation system
JP5479319B2 (en) 2007-04-12 2014-04-23 バイオメット・バイオロジックス・リミテッド・ライアビリティ・カンパニー Buoy suspension fractionation system
WO2009020612A1 (en) * 2007-08-06 2009-02-12 Stb Lifesaving Technologies, Inc. Methods and dressing for sealing internal injuries
CN101842122B (en) 2007-10-30 2013-12-25 巴克斯特国际公司 Use of regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
CN101214391B (en) * 2007-12-27 2010-05-19 广州倍绣生物技术有限公司 High-efficiency biogum sealant and uses thereof
EP2259774B1 (en) 2008-02-27 2012-12-12 Biomet Biologics, LLC Methods and compositions for delivering interleukin-1 receptor antagonist
EP2254991B1 (en) 2008-02-29 2018-08-22 Biomet Manufacturing, LLC A system and process for separating a material
JP5569398B2 (en) 2008-02-29 2014-08-13 フェッローサン メディカル ディバイス エー／エス Device for promoting hemostasis and / or wound healing
US8012077B2 (en) 2008-05-23 2011-09-06 Biomet Biologics, Llc Blood separating device
JP5292025B2 (en) * 2008-09-09 2013-09-18 一般財団法人化学及血清療法研究所 Carboxylic acid-containing biological tissue adhesive and preparation method thereof
KR101678241B1 (en) 2008-12-11 2016-11-21 백스터 인터내셔널 인코포레이티드 Preparations based on fibrinogen and sulfated polysaccharides
US8409606B2 (en) * 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
US8187475B2 (en) 2009-03-06 2012-05-29 Biomet Biologics, Llc Method and apparatus for producing autologous thrombin
US8313954B2 (en) 2009-04-03 2012-11-20 Biomet Biologics, Llc All-in-one means of separating blood components
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
PT2442835E (en) 2009-06-16 2015-03-23 Baxter Healthcare Sa Hemostatic sponge
US9011800B2 (en) 2009-07-16 2015-04-21 Biomet Biologics, Llc Method and apparatus for separating biological materials
EP2477617B1 (en) 2009-09-18 2018-01-31 Bioinspire Technologies Inc. Free-standing biodegradable patch
US9271925B2 (en) 2013-03-11 2016-03-01 Bioinspire Technologies, Inc. Multi-layer biodegradable device having adjustable drug release profile
FR2952641B1 (en) 2009-11-18 2012-01-13 Lfb Biomedicaments PROCESS FOR TREATING BLOOD PLASMA COMPRISING A DISPERSION WASH STEP
KR101811070B1 (en) 2009-12-16 2017-12-20 백스터 인터내셔널 인코포레이티드 Hemostatic sponge
SA111320355B1 (en) 2010-04-07 2015-01-08 Baxter Heathcare S A Hemostatic sponge
US8591391B2 (en) 2010-04-12 2013-11-26 Biomet Biologics, Llc Method and apparatus for separating a material
US9084728B2 (en) 2010-06-01 2015-07-21 Baxter International Inc. Process for making dry and stable hemostatic compositions
KR101957625B1 (en) 2010-06-01 2019-03-12 백스터 인터내셔널 인코포레이티드 Process for making dry and stable hemostatic compositions
EP2575776B1 (en) 2010-06-01 2018-05-30 Baxter International Inc Process for making dry and stable hemostatic compositions
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
JP6195569B2 (en) 2011-10-11 2017-09-13 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Hemostatic composition
CA2851338C (en) 2011-10-11 2019-11-05 Baxter International Inc. Hemostatic compositions
DK2771027T3 (en) 2011-10-27 2015-11-02 Baxter Int hemostatic compositions
CA2865349C (en) 2012-03-06 2021-07-06 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
CA2874290C (en) 2012-06-12 2020-02-25 Ferrosan Medical Devices A/S Dry haemostatic composition
US9642956B2 (en) 2012-08-27 2017-05-09 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
CN105358071B (en) 2013-06-21 2018-07-31 弗罗桑医疗设备公司 The dry composition of vacuum expansion and syringe for retaining the dry composition
CA2928963C (en) 2013-12-11 2020-10-27 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
WO2016058612A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
EP3237041B1 (en) 2014-12-24 2020-01-29 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US9713810B2 (en) 2015-03-30 2017-07-25 Biomet Biologics, Llc Cell washing plunger using centrifugal force
US9757721B2 (en) 2015-05-11 2017-09-12 Biomet Biologics, Llc Cell washing plunger using centrifugal force
BR112017027695A2 (en) 2015-07-03 2018-09-04 Ferrosan Medical Devices As first and second substance retention and mixing syringe
MX2020011866A (en) 2018-05-09 2021-01-20 Ferrosan Medical Devices As Method for preparing a haemostatic composition.
US20230210958A1 (en) 2021-12-30 2023-07-06 Baxter International Inc. Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA448302A (en) * 1948-05-04 Joseph Cohn Edwin Plastic product and process
GB1195061A (en) * 1966-05-27 1970-06-17 Fmc Corp Coated Structures and Methods of Forming Them.
US3523807A (en) * 1966-11-25 1970-08-11 Mihaly Gerendas Method of making a cross-linked fibrin prosthesis
US4265233A (en) * 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
AT359652B (en) * 1979-02-15 1980-11-25 Immuno Ag METHOD FOR PRODUCING A TISSUE ADHESIVE

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290918A (en) * 1993-02-23 1994-03-01 Haemacure Biotech Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"

Also Published As

Publication number Publication date
SE462613B (en) 1990-07-30
DE3002934C2 (en) 1983-12-29
CH649711A5 (en) 1985-06-14
IT1141211B (en) 1986-10-01
NL8000935A (en) 1980-08-19
SE453799B (en) 1988-03-07
JPS6340546B2 (en) 1988-08-11
DK65580A (en) 1980-08-16
SE453799C (en) 1998-03-20
ATA118979A (en) 1980-04-15
IT8019910A0 (en) 1980-02-14
FR2448900B1 (en) 1984-09-07
FR2448900A1 (en) 1980-09-12
GB2041942A (en) 1980-09-17
GB2041942B (en) 1983-04-13
US4362567A (en) 1982-12-07
ES8101381A1 (en) 1980-12-16
DK150815B (en) 1987-06-29
JPS55110556A (en) 1980-08-26
NL190714B (en) 1994-02-16
ES488430A0 (en) 1980-12-16
US4414976A (en) 1983-11-15
DE3002934A1 (en) 1980-08-28
SE8902377D0 (en) 1989-06-30
AT359652B (en) 1980-11-25
BE881466A (en) 1980-05-16
SE8000469L (en) 1980-08-16

Similar Documents

Publication Publication Date Title
CA1128859A (en) Tissue adhesive
CA1119516A (en) Tissue adhesive
CA2113660C (en) Process for the obtention of biological adhesive made of concentrated coagulation factors by salting-out
US5260420A (en) Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
KR100197930B1 (en) Fibrin sealant delivery method
CA1168982A (en) Tissue adhesive
EP0602173B1 (en) Topical fibrinogen complex
JP3367698B2 (en) Stable fibrinogen solution
JPS5838216A (en) Condensed blood plasma derivative
US4621631A (en) Process for the production of a bonded collagen fiber sheet
JP2896235B2 (en) Topical fibrinogen complex
NZ203164A (en) Solid fibrinogen formulation
EP1043034A1 (en) Adhesive for biological tissue
US10456500B2 (en) Implantable preparations for regeneration of tissues and treatment of wounds, their method of preparation, and method of treatment of patients with said implantable preparations
JPH02114A (en) Contentrate of tropine coagulable protein, its production and use thereof in treatment
JPH02129224A (en) Preparation of fibrin
AU727822B2 (en) Compositions useful as fibrin sealants
FI96918C (en) Composition for stabilizing blood plasma during pasteurization

Legal Events

Date Code Title Description
MKEX Expiry